Spreading of hepatitis C virus subtypes 1a and 1b through the central region of Argentina.

Infect Genet Evol

Cátedra de Virología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina. Electronic address:

Published: August 2014


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The recent history of the hepatitis C virus (HCV) subtypes 1a and 1b in the central region of Argentina is hypothesized by phylogeographic reconstruction using coalescent based Bayesian analyses. Direct partial E2 sequences from HCV 1a and 1b infected patients attending different health-care centers of the country were analyzed. The inferred date of the most recent common ancestor (tMRCA) for HCV-1a was: 1962 (between 1943 and 1977) and for HCV-1b was earlier: 1929 (between 1895 and 1953). Diverse ancestral populations were inferred from both subtypes in Córdoba and in Buenos Aires cities and after that, HCV spread within and between larger cities and to other smaller cities. The analyses suggested that HCV-1b was dispersed first and it is currently in a stationary phase whereas HCV-1a was dispersed latter and it is still in a growth phase. Finally, as it was observed in the developed countries, while the transmission of HCV-1b appears to have been somehow prevented, the HCV-1a may still represent a concern in the public health. Further work should be carried out to address their current transmission rate (and its main transmission route) in the Argentinean population.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meegid.2014.05.008DOI Listing

Publication Analysis

Top Keywords

hepatitis virus
8
subtypes central
8
central region
8
region argentina
8
spreading hepatitis
4
virus subtypes
4
argentina history
4
history hepatitis
4
virus hcv
4
hcv subtypes
4

Similar Publications

[Hepatitis A-E: the essentials].

Rev Med Suisse

August 2025

Service de gastroentérologie et d'hépatologie, Département de médecine, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.

Viral hepatitis is associated with high morbidity and mortality worldwide. Hepatitis A and E viruses are enterally transmitted and typically cause acute self-limited hepatitis. Hepatitis B, C, and D viruses are parenterally transmitted and can cause chronic hepatitis, with potential progression to cirrhosis and hepatocellular carcinoma.

View Article and Find Full Text PDF

Background: The pathophysiological changes driving incident kidney cancer remain unclear. This study aimed to identify protein biomarkers and underlying mechanisms using pre-diagnostic plasma proteomics.

Materials And Methods: Among 48,851 UK Biobank participants, 165 were diagnosed with kidney cancer, and 2,911 plasma proteins were analyzed.

View Article and Find Full Text PDF

Interferon-induced miR-7705 modulates the anti-virus activity of cholesterol 25-hydroxylase.

J Virol

September 2025

Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin, China.

Unlabelled: Cholesterol 25-hydroxylase (CH25H), an interferon-stimulated gene (ISG), has been implicated in broad-spectrum antiviral immunity. Here, we identify CH25H as a potent suppressor of hepatitis B virus (HBV) replication that significantly outperforms IFN-α in reducing HBV DNA, pregenomic RNA (pgRNA), HBsAg, and HBeAg, without inducing cytotoxicity. However, CH25H is weakly expressed in hepatocytes and only modestly induced by type I interferon.

View Article and Find Full Text PDF

Background: Vaccination is a key strategy to reduce infectious disease mortality. In pediatric heart transplant recipients (HTRs), the use of immunosuppressive therapy weakens immune responses, increasing the risk of viral infections. This study aimed to evaluate the immunogenicity of hepatitis B virus (HBV) revaccination in this vulnerable population.

View Article and Find Full Text PDF

Aim: Hepatitis C virus (HCV) infection remains a global health concern. Although the World Health Organization (WHO) proposed a strategy to eliminate HCV by 2030, Japan faces challenges owing to limited access and insufficient support for high-risk populations. Previously, HCV diagnoses required a two-step process, delaying results and increasing costs.

View Article and Find Full Text PDF